Aslan Pharmaceuticals has entered into an agreement with Bristol-Myers Squibb to develop an investigational small molecule inhibitor of MET receptor tyrosine kinase, BMS-777607, for treating solid tumours.

Aslan will have rights to develop and market BMS-777607 in Australia, China, Korea, Taiwan and other Asian countries, while Bristol-Myers Squibb will retain rights in the rest of the countries.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Under a pre-agreed development programme, the two parties will develop BMS-777607 against gastric cancer and lung cancer.

Francis Cuss, senior vice-president of research at Bristol-Myers Squibb, said that the partnership will work to produce high-quality data that may be used to further develop and commercialise the medicine worldwide.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact